1338346-52-3

Basic information

• Product Name: 2,4-bis(4'-fluorophenethylamino)-6-(5'-(N,N-dimethylamino)pentylamino)-1,3,5-triazine
• CAS NO: 1338346-52-3
• Molecular Weight: 483.608
• Mol File: 1338346-52-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,4-bis(4'-fluorophenethylamino)-6-(5'-(N,N-dimethylamino)pentylamino)-1,3,5-triazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-bis(4'-fluorophenethylamino)-6-(5'-(N,N-dimethylamino)pentylamino)-1,3,5-triazine(1338346-52-3)
• EPA Substance Registry System: 2,4-bis(4'-fluorophenethylamino)-6-(5'-(N,N-dimethylamino)pentylamino)-1,3,5-triazine(1338346-52-3)

Safety Data

• Hazardous Substances Data: 1338346-52-3(Hazardous Substances Data)

Upstream product

• 1583-88-6 4-fluoro-2-phenethylamine 
• 1338346-87-4 2-chloro-4,6-bis(4'-fluorophenethylamino)-1,3,5-triazine 
• 3209-46-9 N,N-dimethyl-1,5-pentanediamine 

Relevant articles and documents

Triazine-based vanilloid 1 receptor open channel blockers: Design, synthesis, evaluation, and SAR analysis

The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pressing need for improved TRPV1 antagonists, the development of which will require identification of new pharmacophore scaffolds. Uncompetitive antagonists acting as open-channel blockers might serve as activity-dependent blockers that preferentially modulate the activity of overactive channels, thus displaying fewer side effects than their competitive counterparts. Herein we report the design, synthesis, biological evaluation, and SAR analysis of a family of triazine-based compounds acting as TRPV1 uncompetitive antagonists. We identified the triazine 8aA as a potent, pure antagonist that inhibits TRPV1 channel activity with nanomolar efficacy and strong voltage dependency. It represents a new class of activity-dependent TRPV1 antagonists and may serve as the basis for lead optimization in the development of new analgesics.